Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

USV Private Limited

US Class II Ongoing · initiated 2025-10-09

Failed Impurities/Degradation Specifications: The result for 'Any individual unspecified impurity' exceeds the specification limit.

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-10-09

CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.

ASTRAZENECA PHARMACEUTICALS

US Class II Ongoing · initiated 2025-10-08

Lack of Assurance of Sterility:

Mohamed Hagar

US Class I Ongoing · initiated 2025-10-08

Marketed Without an Approved NDA/ANDA-FDA analysis revealed undeclared sildenafil (13.1 mg/capsule) and tadalafil (13.8 mg/capsule).

Sandoz Lisinopril HCT 20/25mg

Canada Type II Ongoing · initiated 2025-10-08

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2025-10-07

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) inst…

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2025-10-07

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit fo…

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2025-10-07

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit fo…

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2025-10-07

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit fo…

VIONA PHARMACEUTICALS INC

US Class II Ongoing · initiated 2025-10-06

Discoloration

Heritage Pharmaceuticals Inc

US Class II Ongoing · initiated 2025-10-06

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc

US Class II Ongoing · initiated 2025-10-06

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc

US Class II Ongoing · initiated 2025-10-06

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc

US Class II Ongoing · initiated 2025-10-06

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc

US Class II Ongoing · initiated 2025-10-06

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc

US Class II Ongoing · initiated 2025-10-06

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Advanced Pharmaceutical Technology, Inc.

US Class II Ongoing · initiated 2025-10-03

Lack of Assurance of Sterility: Potential microbial contamination of subcutaneous pellets.

Church & Dwight Co., Inc.

US Class II Ongoing · initiated 2025-10-01

Labeling: Label Mix-up: The product in the bottle contains elderberry and the label failed to indicate the inclusion of elderberry as an ingredient.

Aspiro Pharma Limited

US Class II Ongoing · initiated 2025-10-01

Presence of Particulate Matter: Particulate matter identified as glass

AHCC

Canada Type II Ongoing · initiated 2025-10-01

Product safety. Verify if your product is affected.Stop taking the product if you have milk allergy .Consult your healthcare provider for any health concerns.Co…

Acella Pharmaceuticals, LLC

US Class II Ongoing · initiated 2025-09-29

Failed dissolution specifications: Stability testing found that the lot did not meet dissolution specifications.

Acuity Specialty Products, Inc.

US Class II Ongoing · initiated 2025-09-29

cGMP deviations: The recall was initiated because required receipt testing of incoming alcohol components used to manufacture the listed hand sanitizers was not…

Acuity Specialty Products, Inc.

US Class II Ongoing · initiated 2025-09-29

cGMP deviations: The recall was initiated because required receipt testing of incoming alcohol components used to manufacture the listed hand sanitizers was not…

Medline Industries, LP

US Class II Ongoing · initiated 2025-09-29

Subpotent Drug

Dr. Reddy's Laboratories, Inc.

US Class II Ongoing · initiated 2025-09-26

Out-of-Specification (OOS) result during the 6-month stability testing; decreased preservative concentration.